Why the study?
Does the concomitant use of rifampin or anticonvulsants alter the pharmacokinetics of quinidine?
Does the concomitant use of rifampin or anticonvulsants alter the pharmacokinetics of quinidine?
Hepatic-enzyme induction by anticonvulsants or rifampin can significantly reduce the half-life of quinidine, necessitating cautious dosage adjustments.
May warrant quinidine monitoring with these anticonvulsants; leaves open rifampin effects and needs prospective validation.
DRUG interactions with quinidine are likely to be clinically important, since quinidine is used in the treatment and prophylaxis of potentially serious arrhythmias, and since there is a relatively narrow range between the therapeutic and toxic concentrations.1 An interaction between quinidine and the anticonvulsant drugs primidone and phenobarbital has led to a reduction in the half-life of quinidine of approximately 50 per cent.1 Enhanced quinidine elimination after hepatic-enzyme induction by the anticonvulsants was suggested as the likely mechanism. A cautious approach in determining the dosage of quinidine was urged for patients who were receiving this drug and had any change . . .
No takes yet. Share an insight, caveat, or question.
Twum-Barima et al. (1981) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: